Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports

Table 1 Clinical features of the four cases

Cases	Age/gender	Duration	Absolute value of eosinophils at baseline	Duration of treatment for absolute value of eosinophils decreased to normal range	Total serum IgE at baseline	Duration of treatment for total IgE decreased to normal range	EASI at baseline	EASI at 16 wk of treatment	VAS at baseline	VAS at 16 wk of treatment	DLQI at baseline	DLQI at 16 wk of treatment
Case 1	37 yr/male	14 yr	6.30 × 109/L	6 wk	277.30 IU/mL	10 wk	62	16	10	1	22	3
Case 2	67 yr/male	10 yr	0.10 × 109/L	-	54.20 IU/mL	-	36	10	8	0	19	1
Case 3	20 yr/male	6 yr	0.20 × 109/L	-	1002 IU/mL	12 wk	16	4	6	0	16	2
Case 4	54 yr/female	5 yr	2.0 × 109/L	10 wk	893.60 IU/mL	14 wk	23	8	7	0	17	1

Range of the normal absolute value of eosinophils: 0.00-0.52 (× 10⁹/L); Total serum IgE: < 100 IU/mL. EASI: Eczema area and severity index (0-72 scores); VAS: The pruritus visual analog scale (0-10 scores) (with the zero indicating no pruritus and 10 indicates most severe pruritus); DLQI: Dermatology life quality index (0-30 scores).